MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8

Overview

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy. It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence. The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication. Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions

  • Chronic Back Pain
  • Duodenal Ulcer
  • Erosive Esophagitis
  • Extra-Articular Rheumatism
  • Gastritis
  • Heartburn
  • Helicobacter Pylori Infection
  • Multiple Endocrine Neoplasia
  • Muscle Spasms
  • Nonspecific Pain Post Traumatic Injury
  • Osteoarthritis (OA)
  • Postoperative pain
  • Stress Ulcers
  • Symptomatic Non-erosive Gastroesophageal Reflux Disease
  • Zollinger-Ellison Syndrome
  • Active Gastric ulcer
  • Acute Duodenal Ulcers
  • Gastrointestinal ulceration
  • Pathological hypersecretory conditions

FDA Approved Products

FAMOTIDINE
Manufacturer:ST. MARY'S MEDICAL PARK PHARMACY
Route:ORAL
Strength:40 mg in 1 1
Approved: 2023/06/22
NDC:60760-843
Famotidine
Manufacturer:Unit Dose Services
Route:ORAL
Strength:20 mg in 1 1
Approved: 2017/05/04
NDC:50436-1000
FAMOTIDINE
Manufacturer:Camber Pharmaceuticals, Inc.
Route:ORAL
Strength:40 mg in 5 mL
Approved: 2023/08/23
NDC:31722-063
FAMOTIDINE
Manufacturer:Zydus Lifesciences Limited
Route:INTRAVENOUS
Strength:40 mg in 4 mL
Approved: 2023/08/02
NDC:70771-1846
Famotidine
Manufacturer:Athenex Pharmaceutical Division, LLC.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2024/03/03
NDC:70860-752

Singapore Approved Products

FAMOTIN TABLET 40 mg
Manufacturer:PT ACTAVIS INDONESIA
Form:TABLET
Strength:40 mg
Online:Yes
Approved: 1993/12/06
Approval:SIN07568P
PHARMA FAMOTIDINE TABLET 20 mg
Manufacturer:KOREA PHARMA CO LTD
Form:TABLET, FILM COATED
Strength:20 mg
Online:Yes
Approved: 1998/11/27
Approval:SIN10470P
FAMODINE TABLET 20 mg
Manufacturer:DUOPHARMA (M) SDN BHD
Form:TABLET
Strength:20 mg
Online:Yes
Approved: 1997/01/15
Approval:SIN09129P
FAMOC 40 TABLET 40 mg
Manufacturer:BERLIN PHARMACEUTICAL INDUSTRY CO LTD
Form:TABLET, FILM COATED
Strength:40 mg
Online:Yes
Approved: 1998/10/26
Approval:SIN10291P
SUNPEPCIN 40 TABLET 40 mg
Manufacturer:SUNWARD PHARMACEUTICAL PRIVATE LIMITED
Form:TABLET, FILM COATED
Strength:40 mg
Online:Yes
Approved: 1998/12/31
Approval:SIN10596P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath